Zhao Xin-yan, Wang Bao-en, Wang Tai-ling, Li Xin-min
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Zhonghua Yi Xue Za Zhi. 2006 Sep 26;86(36):2563-6.
To investigate the antifibrotic effects of silymarin on hepatic fibrosis.
Sixty-one male Wistar rats were randomly divided into three groups: control group (15 rats); DMN model group (23 rats), injected intraperitoneally with dimethylnitrosamine (DMN) 10 mg/kg twice per week for 8 weeks to induce hepatic fibrosis; and silymarin group (23 rats), injected intraperitoneally with DMN and given silymarin 50 mg/kg by gastric gavage daily for 8 weeks. Eight weeks late all rats were sacrificed. Blood samples were collected to measure the alanine transaminase (ALT), aspirate aminotransferase (AST), albumin, and total bilirubin (TBIL). The hydroxyproline (Hyp) content in the liver tissue was measured. The histopathological changes as well as the fibrosis stages and score were examined by microscopy.
The levels of ALT, AST, and TBIL of the silymarin groups were 59 U/L +/- 19 U/L, 159 U/L +/- 39 U/L, and mean rank 24 respectively, all significantly lower than those of the DMN model group (128 U/L +/- 25 U/L, 246 U/L +/- 61 U/L, and mean rank 37 respectively, P < 0.01, P = 0.001, and P = 0.003). Compared with DMN rats, the level of Hyp of the silymarin was lower by 42.6%, the hepatic score of the silymarin was 6.2 +/- 2.4, significantly than that of the DMN model group (12.8 +/- 4.4, P = 0.001), and more cases in the silymarin group were at the lower stages.
Silymarin markedly inhibits and reverse the progression of hepatic fibrosis induced by dimethylnitrosamine.
研究水飞蓟素对肝纤维化的抗纤维化作用。
61只雄性Wistar大鼠随机分为三组:对照组(15只大鼠);二甲基亚硝胺(DMN)模型组(23只大鼠),每周两次腹腔注射10 mg/kg二甲基亚硝胺(DMN),共8周以诱导肝纤维化;水飞蓟素组(23只大鼠),腹腔注射DMN并每天灌胃给予50 mg/kg水飞蓟素,共8周。8周后处死所有大鼠。采集血样检测丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、白蛋白和总胆红素(TBIL)。检测肝组织中羟脯氨酸(Hyp)含量。通过显微镜检查组织病理学变化以及纤维化阶段和评分。
水飞蓟素组的ALT、AST和TBIL水平分别为59 U/L±19 U/L、159 U/L±39 U/L和平均秩次24,均显著低于DMN模型组(分别为128 U/L±25 U/L、246 U/L±61 U/L和平均秩次37,P<0.01、P = 0.001和P = 0.003)。与DMN大鼠相比,水飞蓟素组的Hyp水平降低了42.6%,水飞蓟素组的肝评分为6.2±2.4,显著低于DMN模型组(12.8±4.4,P = 0.001),且水飞蓟素组更多病例处于较低阶段。
水飞蓟素显著抑制并逆转二甲基亚硝胺诱导的肝纤维化进展。